XML 55 R46.htm IDEA: XBRL DOCUMENT v3.23.3
STOCK BASED COMPENSATION (Tables)
9 Months Ended
Sep. 30, 2023
STOCK BASED COMPENSATION  
Schedule of option activity

The option activity of the Plans for the nine months ended September 30, 2023, is as follows (shares in thousands):

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

    

​

    

Weighted-Average 

 

​

​

​

​

​

​

Weighted-Average 

​

Remaining 

 

Aggregate

​

​

Number of 

​

Exercise Price 

​

Contractual Term 

 

Intrinsic Value

​

    

Shares

    

per Share

    

(in years)

 

(in thousands)

Outstanding at January 1, 2023

​

8,423

​

$

1.83

 

6.02

​

$

922

Exercised

 

(1,006)

​

$

1.20

​

​

​

​

​

Forfeited/expired

 

(1,126)

​

$

2.41

​

​

​

​

​

Outstanding at September 30, 2023

 

6,291

​

$

1.83

​

5.24

​

​

989

Options vested at September 30, 2023

 

5,693

​

$

1.86

​

5.08

​

​

954

Options vested or expected to vest at September 30, 2023

 

6,287

​

$

1.83

​

5.24

​

​

989

Schedule of RSU activity under the Plan

The activity for stock subject to vesting as of September 30, 2023, is as follows (shares in thousands):

​

​

​

​

​

​

​

​

Shares Subject 

    

Weighted-Average

​

    

to Vesting

    

Grant Date Fair Value

Balance of unvested shares as of January 1, 2023

​

102

 

$ 8.78

Vested

 

(85)

​

$ 8.78

Balance of unvested shares as of September 30, 2023

 

17

 

$ 8.78

Schedule of RSU activity

RSU activity under the 2020 Plan for the nine months ended September 30, 2023, is as follows (shares in thousands):

​

​

​

​

​

​

​

​

Shares Subject 

    

Weighted-Average

​

    

to Vesting

    

Grant Date Fair Value

Balance of unvested shares as of January 1, 2023

​

22,145

​

$ 4.15

Granted

​

9,677

​

$ 1.86

Vested

​

(4,062)

​

$ 5.28

Cancelled/Forfeited

​

(2,278)

​

$ 4.57

Balance of unvested shares as of September 30, 2023

​

25,482

​

$ 3.07

Schedule of stock-based compensation expense

Total stock-based compensation expense related to all of the Company’s stock-based awards granted is reported in the condensed consolidated statements of operations as follows (in thousands):

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended September 30, 

​

Nine Months Ended September 30, 

​

​

2023

    

2022

    

2023

    

2022

Research and development

​

$

3,662

​

$

4,355

​

$

12,612

​

$

21,872

General and administrative expense

​

 

2,802

​

 

3,899

​

 

10,419

​

 

11,681

Sales and marketing expense

​

 

702

​

 

3,052

​

 

1,881

​

 

5,725

Cost of sales

​

 

517

​

 

734

​

 

1,787

​

 

1,892

Total stock-based compensation expense

​

$

7,683

​

$

12,040

​

$

26,699

​

$

41,170